Page 64 - Aet News Today

While telemedicine seems to be the ideal solution to this ever-increasing shortage problem, it still has challenges and benefits that need to be considered before deciding to add a telemedicine program of your own.

In a letter to Senate leadership, several organizations asked for the passing of legislation that would reform the patent system and improve competition in the prescription drug space.

A webinar on December 5 will spotlight expert panelists from Praia Health and Providence, interviewed by AVIA, to discuss the benefits of adopting a hyperpersonal care model for patients, challenges that health systems face providing this care, and how they can overcome them.

Patients deserve agency over their own bodies and care, and clinicians, educators, and caregivers can be those catalysts needed to promote disability rights in healthcare practices across the industry.

BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé will retire in December, when he will be succeeded by Genentech CEO Alexander Hardy. The transition comes with BioMarin in the early stages of the commercial launch of Roctavian, the first FDA-approved hemophilia A gene therapy.

Jona, a New York-based gut microbiome testing startup, emerged from stealth with $5 million in funding. The company's at-home microbiome profiling kit educates users about how the community of microorganisms residing in their gut impacts their overall health. The platform also offers recommendations concerning diet and lifestyle modifications based on users’ personal health goals.

BeMe Health, a digital mental health company for teens, is teaming up with Inland Empire Health Plan and Molina Healthcare of California to bring BeMe's platform to 10 local educational agencies. The partnership will support more than 72,000 teens.

Eli Lilly is acquiring Beam Therapeutics’ opt-in rights to three Verve Therapeutics gene-editing therapies for cardiovascular conditions. The deal comes four months after the pharmaceutical giant began a partnership on a preclinical Verve gene-editing therapy for a different target.

While legacy pharma companies battle in court with government agencies over how to address the costs that result from antiquated drug development paradigms, a growing cadre of compute-enabled life science companies are unlocking the nascent power of next-generation compute technologies to transform drug discovery and development.

Medicare Advantage members have fewer readmissions, fewer preventable hospitalizations and lower rates of high-risk medication use than traditional Medicare, new research by Harvard Medical School and Inovalon shows.